Inactive Instrument

Press Releases Capricor Therapeutics Inc Nasdaq

Equities

US14070B1017

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	Apr. 24	AQ
Capricor Therapeutics to Present at Upcoming Investor Conferences	Mar. 21	AQ
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	Mar. 06	AQ
Capricor: Q4 Earnings Snapshot	Feb. 29	AQ
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Feb. 29	AQ
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy	Feb. 27	AQ
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29	Feb. 22	AQ
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization	Feb. 20	AQ
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2	Jan. 24	AQ
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis	Dec. 11	AQ
Capricor: Q3 Earnings Snapshot	Nov. 14	AQ
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 14	AQ
Brain Hemorrhage Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 14	AQ
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14	Nov. 07	AQ
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program	23-10-19	AQ
Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society	23-10-10	AQ
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy	23-10-02	AQ
Capricor Therapeutics Announces $23 Million Registered Direct Offering	23-10-02	AQ
Capricor Therapeutics Announces $23 Million Registered Direct Offering	23-09-29	AQ
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy	23-09-29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Capricor Therapeutics Inc Nasdaq

Equities

US14070B1017

Press Releases

Filters